Sign In  |  Register  |  About Los Altos  |  Contact Us

Los Altos, CA
September 01, 2020 1:26pm
7-Day Forecast | Traffic
  • Search Hotels in Los Altos

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

Incyte to Report Third Quarter Financial Results

Incyte (Nasdaq:INCY) announced today that it has scheduled its third quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, October 29, 2024.

The schedule for the press release and conference call/webcast is as follows:

Q3 2024 Press Release:

October 29, 2024 at 7:00 a.m. ET

Q3 2024 Conference Call:

October 29, 2024 at 8:00 a.m. ET

Domestic Dial-In Number:

877-407-3042

International Dial-In Number:

201-389-0864

Conference ID Number:

13749146

If you are unable to participate, a replay of the conference call will be available for thirty days. The replay dial-in number for the U.S. is 877-660-6853 and the dial-in number for international callers is 201-612-7415. To access the replay you will need the conference ID number 13749146.

The live webcast with slides can be accessed at Investor.Incyte.com and will be available for replay for ninety days.

About Incyte

A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia.

For additional information on Incyte, please visit Incyte.com or follow us on social media: LinkedIn, X, Instagram, Facebook, YouTube.

Contacts

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 LosAltos.com & California Media Partners, LLC. All rights reserved.